Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
详细信息 查看全文
- 作者：Seong Yoon Yi (1)
Jin Seok Ahn (1)
Ji Eun Uhm (1)
Do Hyoung Lim (1)
Sang Hoon Ji (1)
Hyun Jung Jun (1)
Kyoung Ha Kim (1)
Myung Hee Chang (1)
Min Jae Park (1)
Eun Yoon Cho (2)
Yoon La Choi (2)
Yeon Hee Park (1)
Young-Hyuck Im (1) - 刊名：BMC Cancer
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：10
- 期：1
- 全文大小：347KB
- 参考文献：1. Dinh P, Sotiriou C, Piccart MJ: The evolution of treatment strategies: Aiming at the target. / Breast 2007,16(suppl 2):S10-S6. CrossRef
2. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Sortiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. / Clin Cancer Res 2008, 14:5158鈥?165. CrossRef
3. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K. Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortogagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. / Clin Cancer Res 2005, 11:5678鈥?685. CrossRef
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. / Clin Cancer Res 2007, 13:2329鈥?334. CrossRef
5. Perou CM, S酶rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L酶nning PE, B酶rresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. / Nature 2000, 406:747鈥?52. CrossRef
6. S酶rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein L酶nning P, B酶rresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. / Proc Natl Acad Sci USA 2001, 98:10869鈥?0874. CrossRef
7. S酶rlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, L酶nning P, Brown PO, B酶rresen-Dale AL. Botstein D: Repeated observation of breast tumor subtypes in independent gene expression data sets. / Proc Natl Acad Sci USA 2003, 100:8418鈥?423. CrossRef
8. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population based study. / Proc Natl Acad Sci USA 2003, 100:10393鈥?0398. CrossRef
9. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. / JAMA 2006, 295:2492鈥?502. CrossRef
10. Chia K, Tutt A: Triple negative breast cancer: an update. / Adv Breast Cancer 2007,4(3):75鈥?0.
11. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. / Clin Cancer Res 2007, 13:4429鈥?434. CrossRef
12. Bauer KR, Brown M, Cress RD, Parise CA, Caqqiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. / Cancer 2007,109(9):1721鈥?728. CrossRef
13. Kilburn LS, the TNT trial management group: 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. / Clin Oncol (R Coll Radio) 2008,20(1):35鈥?9. CrossRef
14. Rakha EA, EI-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. / Cancer 2007,109(1):25鈥?2. CrossRef
15. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. / Nat Rev Cancer 2004,4(10):814鈥?19. CrossRef
16. Diaz LK, Cryns VL, Symmans WF, Sneige N: Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. / Adv Anat Pathol 2007,14(6):419鈥?30. CrossRef
17. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. / Histopathology 2008, 52:108鈥?18. CrossRef
18. Irvin WJ Jr, Carey LA: What is triple-negative breast cancer? / Eur J Cancer 2008, 44:2799鈥?805. CrossRef
19. A'Hern RP, smith IE, Ebbs RS: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. / Br J Cancer 1993, 67:801鈥?05. CrossRef
20. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systemic review of published randomized trials involving 31,510 women. / J Clin Oncol 1998, 16:3439鈥?460.
21. Green JA, Slater AJ, Campbell IR, Kelly V: Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine. / Breast Cancer Res Treat 1996, 39:155鈥?63. CrossRef
22. Bernett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwriqht K, Dukart G, Reisman A, Schoch I: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. / J Clin Oncol 1988, 6:1611鈥?620.
23. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. / J Clin Oncol 1989, 7:560鈥?71.
24. Crown J, Di茅ras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, Marty M, Misset JL, Osterwalder B, Piccart M: Chemotherapy for metastatic breast cancer - report of a European expert panel. / Lancet Oncol 2002, 3:719鈥?26. CrossRef
25. Pai VB, Nahata MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. / Drug Saf 2000, 22:263鈥?02. CrossRef
26. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweiq M, Muqqia FM: Risk factors for doxorubicin-induced congestive heart failure. / Ann Intern Med 1979, 91:710鈥?17.
27. Hershman DL, Shao T: Anthracycline cardiotoxicity after breast cancer treatment. / Oncology 2009,23(3):227鈥?34.
28. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW: Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. / Ann Oncol 2009,20(5):816鈥?27. CrossRef
29. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP: The role of BRCA1 in the cellular response to chemotherapy. / J Natl Cancer Inst 2004,96(22):1659鈥?668. CrossRef
30. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wi艣niowski R, Siolek M, Narod SA, Lubinski J, Polish Hereditary Breast Cancer Consortium: Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. / Breast Cancer Res Treat 2008, 108:289鈥?96. CrossRef
31. Sirohi B, Arnedos M, Popat S, Ashley S, Nerukar A, Walsh G, Johnston S, Smith IE: Platinum-based chemotherapy in triple-negative breast cancer. / Ann Oncol 2008, 19:1847鈥?852. CrossRef
32. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Im DW, Moon WK, Kim KY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. / BMC Cancer 2007, 7:203. CrossRef
33. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG001 trial. / J Clin Onol 2009, 27:1168鈥?176. CrossRef
34. Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH: Treatment outcomes and cliniopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. / Int J Cancer 2009, 124:1457鈥?462. CrossRef
35. Marty M, Espie M, Cottu PH, Cuvier C, Lerebours F: Optimizing chemotherapy for patients with advanced breast cancer. / Oncology 1999, 57:21鈥?6. CrossRef
36. Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Sch眉tt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S: Triple-negative high-risk breast cancer derived particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. / Ann Oncol 2008, 19:861鈥?70. CrossRef
37. Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG, Hanby A, Lakhani SR: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. / Clin Cancer Res 2004, 10:5988鈥?997. CrossRef
38. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. / Mod Pathol 2006, 19:264鈥?71. CrossRef
39. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielson TO: Basal-like breast cancer defined by five bio-marker has superior prognostic value than triple-negative phenotype. / Clin Cancer Res 2008, 14:1368鈥?376. CrossRef
40. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T: Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. / J Surg Oncol 2008, 97:30鈥?4. CrossRef
41. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, Carmichael J: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. / J Clin Oncol 2009, 27:803s. (abstract # CRA501)
42. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitors in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. / J Clin Oncol 2009, 27:793s. (abstract # 3)
43. Carey LA, Rugo HS, Marcom PK, Irvin W, Ferraro M, Burrow E, He X, Perou CM, Winer EP, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. / J Clin Oncol 2008, 26:43s. (abstract # 1009)
44. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/527/prepub - 作者单位：Seong Yoon Yi (1)
Jin Seok Ahn (1)
Ji Eun Uhm (1)
Do Hyoung Lim (1)
Sang Hoon Ji (1)
Hyun Jung Jun (1)
Kyoung Ha Kim (1)
Myung Hee Chang (1)
Min Jae Park (1)
Eun Yoon Cho (2)
Yoon La Choi (2)
Yeon Hee Park (1)
Young-Hyuck Im (1)
1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, 135-710, Seoul, Korea
2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, 135-710, Seoul, Korea - ISSN：1471-2407
文摘
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis was performed for 110 metastatic breast cancer patients selected on the basis of palliative AC treatment and the availability of immunohistochemical data for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2/neu) status. Results Of the 110 patients analyzed, 71 (64.5%) were hormone receptor positive (HR+), 14 (12.7%) were HER2+, and 25 (22.7%) were triple negative (TN). There were no differences in age, stage at diagnosis, total number of cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver among breast cancer subtypes. The overall response rates to AC were 55.9% for the HR+ subgroup, 42.9% for the HER2+ subgroup, and 56.5% for the TN subgroup. The progression-free survival (PFS) in patients with HER2+ and TN were significantly shorter than in the HR+ (median PFS, 9.1 vs 8.1 vs 11.5 months, respectively; p = 0.0002). The overall survival (OS) was 25.4 months in the TN subgroup and 27.3 months in HER2+ subgroup. The median OS for these two groups was significantly shorter than for patients in the HR+ subgroup (median, 38.5 months; 95% CI, 30.1-46.9 months; p < 0.0001). Conclusions The response to palliative AC chemotherapy did not differ among breast cancer subtypes. Despite chemosensitivity for palliative AC, the TN subtype has a shorter overall survival than non-TN subtypes. Innovative treatment strategies should be developed to slow the course of disease.